A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A*02:01 complex-Reference-Cited by-同舟云学术

A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A*02:01 complex

Published:2022-03-08 Issue:5 Volume:7 Page:
ISSN:2379-3708
Container-title:JCI Insight
language:en
Short-container-title:

Author:

Dao Tao,Mun Sung Soo^ORCID,Molvi Zaki^ORCID,Korontsvit Tatyana,Klatt Martin G.^ORCID,Khan Abdul G.,Nyakatura Elisabeth K.,Pohl Mary Ann^ORCID,White Thomas E.,Balderes Paul J.,Lorenz Ivo C.^ORCID,O’Reilly Richard J.,Scheinberg David A.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://insight.jci.org/articles/view/151624/files/pdf

Reference51 articles.

1. Neoantigens in cancer immunotherapy

2. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

3. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

4. Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients

5. Immunogenicity of somatic mutations in human gastrointestinal cancers

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

2. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity;Frontiers in Immunology;2023-11-17

3. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC/CD3 T cell engagers;Frontiers in Immunology;2023-11-10

4. The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles;Journal for ImmunoTherapy of Cancer;2023-09

5. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells;Molecular Cancer;2023-08-30